CME

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Faculty Disclosure
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationship(s), which have been resolved through an established COI resolution process, and have stated that these reported relationship(s) will not have any impact on their ability to give an unbiased presentation.

Howard Baum, MD
Consulting fees/advisory boards: Novo Nordisk Pharmaceutical Industries, Inc.

Louis Kuritzky, MD
Consulting fees/advisory boards: sanofi-aventis U.S., Novo Nordisk Pharmaceutical Industries, Inc., Eli Lilly and Company

Timothy S. Reid, MD
Consulting fees/advisory boards: Medtronic, sanofi-aventis U.S., Novo Nordisk Pharmaceutical Industries, Inc., Takeda Pharmaceuticals North America, Amylin
Fees received for promotional/non-CME activities: Medtronic, sanofi-aventis U.S., Novo Nordisk Pharmaceutical Industries, Inc., Pfizer, Inc.

Silvio E. Inzucchi, MD
Consulting fees/advisory boards: Merck & Co., Inc., Takeda Pharmaceuticals North America, Novartis Pharmaceuticals, Daiichi Sankyo, Inc., Amylin
Fees received for promotional/non-CME activities: Merck & Co., Inc., Takeda Pharmaceuticals North America, Contracted research: Eli Lilly and Company

Bruce W. Bode, MD
Consulting fees/advisory boards: Novo Nordisk Pharmaceutical Industries, Inc., sanofi-aventis U.S., Medtronic
Fees received for promotional/non-CME activities: Eli Lilly and Company, Novo Nordisk Pharmaceutical Industries, Inc., sanofi-aventis U.S., Merck & Co., Inc., Medtronic
Contracted research: JDRF, Novo Nordisk Pharmaceutical Industries, Inc., Eli Lilly and Company, DexCom, Inc., Johnson & Johnson, GlaxoSmithKline, MannKind Corporation

Helena W. Rodbard, MD, FACP, MACE
Consulting fees/advisory boards: Abbott Laboratories, Novo Nordisk Pharmaceutical Industries, Inc., Takeda Pharmaceuticals North America, GlaxoSmithKline
Fees received for promotional/non-CME activities: Abbott Laboratories, Merck & Co., Inc., Novo Nordisk Pharmaceutical Industries, Inc., sanofi-aventis U.S.
Contracted research: Biodel Inc., sanofi-aventis U.S., Novo Nordisk Pharmaceuticals North America

John L. Leahy, MD
Consulting fees/advisory boards: sanofi-aventis U.S., Merck & Co., Inc., Novo Nordisk Pharmaceutical Industries, Inc.
Fees received for promotional/non-CME activities: Daiichi Sankyo, Inc.

George Dailey, MD
Fees received for promotional/non-CME activities: Merck & Co., Inc.
Contracted research: Boehringer Ingelheim Pharmaceuticals, Inc., Roche Laboratories Inc., Novo Nordisk Pharmaceutical Industries, Inc., MannKind Corporation

Mark W. Stolar, MD
Consulting fees/advisory boards: Takeda Pharmaceuticals North America
Fees received for promotional/non-CME activities: Takeda Pharmaceuticals North America, Amylin, Novo Nordisk Pharmaceutical Industries, Inc.

Bruce Trippe, MD, FACE
Consulting fees/advisory boards: Abbott Laboratories, GlaxoSmithKline
Fees received for promotional/non-CME activities: Novo Nordisk Pharmaceutical Industries, Inc., Merck/Schering-Plough Pharmaceuticals

Dace L. Trence, MD, FACE
Contracted research: Bayer Health Care
Ownership interest (stocks/stock options – excluding mutual funds): Medtronic, sanofi-aventis U.S.

Patrick J. Boyle, MD
Fees received for promotional/non-CME activities: Eli Lilly and Company, Amylin, Takeda Pharmaceuticals North America

Anne Peters, MD, FACP, CDE
Consulting fees/advisory boards: Amylin, Abbott Laboratories, Eli Lilly and Company, Novo Nordisk Pharmaceutical Industries, Inc., Takeda Pharmaceuticals North America, Medtronic MiniMed, Inc.

Doron Schneider, MD
Consulting fees/advisory boards: Novo Nordisk Pharmaceutical Industries, Inc.
Fees received for promotional/non-CME activities: Novo Nordisk Pharmaceutical Industries, Inc.

Donna Rice, MBA, BSN, RN, CDE
Consulting fees/advisory boards: Eli Lilly and Company, Agamatrix, Endocrine Today

Luigi Meneghini, MD
Speakers Bureau: Novo Nordisk Pharmaceutical Industries, Inc, sanofi-aventis U.S., Medtronic, Eli Lilly and Company, Amylin
Consulting fees/advisory boards: Novo Nordisk Pharmaceutical Industries, Inc, sanofi-aventis U.S., Medtronic, NIPRO Diabetes Systems
Fees received for promotional/non-CME activities: list companies
Contracted research: Novo Nordisk Pharmaceutical Industries, Inc, sanofi-aventis U.S., Merck & Company, Inc

Brian P. McDonough, MD, has stated no real or apparent conflicts.

Rachel A. Karcher, PharmD and the other employees of Med-IQ have no financial relationships to disclose.

Learning Objectives:
Upon completion, participants should be able to:

Apply current evidence when using pharmacologic treatment in patients with type 2 diabetes
Explain the benefits and limitations of currently available agents
Implement new pharmacologic strategies to reach HbA1C goals
Identify regional, patient-specific barriers and implement strategies for overcoming those barriers to provide optimal care and improve patient outcomes

Series Overview/Statement of Need
Diabetes mellitus is a worldwide epidemic that has created a crisis for the healthcare system and society. Recent findings from large randomized controlled trials provide clear and compelling evidence that intensive treatment of diabetes mellitus and its known risk factors can significantly decrease the development and/or progression of diabetes-related complications. Achieving glycemic control, treating hypertension, and controlling blood lipid levels are the cornerstones of preventing diabetes-related complications and early death. Furthermore, patient participation in the management of this progressive disease is essential for success.

Primary care physicians play a central role in the management of patients with diabetes, providing care for approximately 90% to 95% of adult patients with type 2 diabetes. The challenges of keeping abreast of recent advances in glycemic control and the prevention and detection of diabetes-related complications is a major barrier to the implementation of optimal management strategies. These intimate, interactive programs are designed to help professionals on the front line of diabetes management understand and implement recent pharmacologic advances and will provide a forum for discussing practical solutions for common clinical challenges.

Target Audience
This activity is intended for primary care physicians, physician assistants, nurse practitioners, and nurses involved in the care of type 2 diabetes patients.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Med-IQ designates this activity for a maximum of 20.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Endorsed by

The Endocrine Society

Evidence-Based Content Statement
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Acknowledgment of Commercial Support
This series is supported by an educational grant from sanofi-aventis U.S.

Medium and Method of Participation/Instructions to Receive Credit
This CME activity consists of 3 stages. To receive credit, each participant must read the introductory CME material, complete all 3 stages, and complete the corresponding attestation and evaluation.